Insmed reports positive 12-month data for TPIP in PAH study.
Insmed announced sustained efficacy and safety for once-daily TPIP, strengthening the potential for the drug to become the prostanoid of choice for PAH patients. These data advance the company's clinical development pipeline.
View filing at SEC.gov →